Platforms & Product
Benchling launches Science Foundries
Agents now run whole R&D workflows, with scientists approving key steps. Benchling calls agents its fastest-growing product.
Read the full story →Revvity Signals unveils LabGistics
AI turns plain-English SOPs into GxP-ready workflows from research to production, shipping in December.
Read the full story →Funding & M&A
OpenAI acquires Orchestra Bio
Drug-programme coordination agents are being folded into OpenAI’s Rosalind life sciences suite. The AI labs are now chasing R&D software budgets.
Read the full story →Albert Invent raises $55M
The chemistry R&D platform grew users 6x year on year, with partners including BASF, Henkel and Clorox.
Read the full story →Capital is concentrating
Two of Q3’s three biggest rounds went to AI drug developers: Chai Discovery ($400M) and Enveda ($311M). Investors are concentrating big cheques in fewer, later-stage companies.
Source: 7 Oct →Leadership Moves
Veeva
Dan Rizzo is now EVP Sales, Consulting & Services. Tom Schwenger has left to become CEO of a Veeva partner.
Read the full story →Nuclera
Carl Raimond, formerly President of Proteomic Sciences at Thermo Fisher, is the new CEO.
Read the full story →Revalia Bio
Casimir Starsiak III, formerly Eli Lilly’s enterprise AI and research software lead, is the new CEO.
Read the full story →Talent Insight
The agent era needs a different commercial team
- Layoffs are down sharply, so fewer good people are on the market and they're harder to hire.
- We’re seeing more searches for Deployment Strategists, Forward Deployed Scientists and scientific CS, alongside VP Sales and CRO roles.
- For 2027 plans: For 2027 plans budget for deployment talent next to your AEs. Lab credibility plus AI fluency is the rarest combination.
Building a team in Life Science Software?
Jack Maclean specialises in Life Science Software hiring at QP Group. Talk to Jack about the market, salaries or a search.
